Juno gets ADORA2A inhibitor in RedoxTherapies takeout

Juno Therapeutics Inc. (NASDAQ:JUNO) acquired RedoxTherapies Inc. (Boston, Mass.) for $10 million in upfront cash and undisclosed milestones. The deal gives Juno vipadenant (V2006), a small molecule adenosine A2A receptor (ADORA2A) antagonist.

Juno said vipadenant may disrupt immunosuppressive pathways in the tumor microenvironment. The company plans to study vipadenant in combination with its engineered T cells. ...